The company reaffirms its 2025 outlook of revenue growth at constant currency ex-COVID of 4 to 7% Adjusted EBITDA margin expansion of up to 20 basis points and Adjusted Diluted Earnings per Share growth of 5 to 9%. These expectations result in full-year revenue guidance of $15,725M to $16,125M, consensus 16.03B…Adjusted EBITDA of $3,765M to $3,885M, and Adjusted Diluted Earnings per Share of $11.70 to $12.10. This revenue guidance assumes just over $100M of COVID-related revenue step-down, entirely in R&DS, approximately 150 basis points of headwind from foreign exchange, and 100-150 basis points of contribution from acquisitions. All financial guidance assumes foreign currency exchange rates as of February 5, 2025 remain in effect for the forecast period.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio